Alteration of Glycosylation Renders HIV Sensitive to Inactivation by Normal Human Serum

Journal of Immunology

Volumn 159, Issue 9, 1997, Pages 4356-4361

  Reed, Deborah J ^a   Lin, Xinli ^b   Thomas, Tim D ^b   Birks, Carl W ^a   Tang, Jordan ^b   Rother, Russell P ^a  

^a ALEXION PHARMACEUTICALS   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN;

ANIMAL; ARTICLE; BLOOD; CELL LINE; CELLULAR IMMUNITY; GENETIC TRANSFECTION; GENETICS; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; SWINE;

ANIMALS; CELL LINE; GLYCOSYLATION; HIV ANTIBODIES; HIV ANTIGENS; HIV SEROPOSITIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNODOMINANT EPITOPES; SWINE; TRANSFECTION;

EID: 0031279286     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Banapour, B., J, Sernatinger, and J. A. Levy. 1986. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 152:268.
2. Hoshino, H., H. Tanaka, M. Miwa, and H. Okada. 1984. Human T-cell leukemia virus is not lysed by human serum. Nature 310:324.
3. Welsh, R. M., Jr., N. R. Cooper, F. C. Jensen, and M. B. A. Oldstone. 1975. Human serum lyses RNA tumour viruses. Nature 257:612.
4. Welsh, R. M., Jr., F. C. Jensen, N. R. Cooper, and M. B. A. Oldstone. 1976. Inactivation and lysis of oncornaviruses by human serum. Virology 74:432.
5. Cooper, N. R., F. C. Jensen, Jr., M. W. Welsh, and M. B. A. Oldstone. 1976. Lysis of RNA tumor viruses by human serum: direct antibody-independent triggering of the classical complement pathway. J. Exp. Med. 144:970.
6. Bartholomew, R. M., and A. F. Esser. 1980. Mechanism of antibody-independent activation of the first component of complement (C1) on retrovirus membranes. Biochemistry 19:2847.
7. Bartholomew, R. M., A. F. Esser, and H. J. Muller-Eberhard. 1978. Lysis of oncomaviruses by human serum: isolation of the viral complement (C1) receptor and identification as p15E. J. Exp. Med. 147:844.
8. Solder, B. M., T. F. Schulz, P. Hengster, J. Lower, C. Larcher, G. Bitterlich, R. Kurth, H. Wachter, and M. P. Dierech. 1989. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol. Lett. 22:135.
9. Ebenbichler, C. F., N. M. Thielens, R. Vornhagen, P. Marschang, G. J. Arlaud, and M. P. Dierech. 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174:1417.
10. June, R. A., S. Z. Schade, M. J. Bankowski, M. Kuhns, A. McNamara, T. F. Lint, A. L. Landay, and G. T. Spear. 1991. Complement and antibody mediate enhancement of HIV infection by increasing virus binding and provirus formation. AIDS 5:269.
11. Rother, R. P., W. L. Fodor, J. P. Springhorn, C. W. Birks, E. Setter, M. S. Sandrin, S. P. Squinto, and S. A. Rollins. 1995. A novel mechanism of retrovirus inactivation in human serum mediated by anti-agalactosyl natural antibody. J. Exp. Med. 182:1345.
12. Takeuchi, Y., C. D. Porter, K. M. Strahan, A. F. Preece, K. Gustafsson, J.-L. Cosset, R. A. Weiss, and M. K. L. Collins. 1996. Sensitization of cells and retroviruses to human serum by (α1-3) galactosyltransferase. Nature 379:85.
13. Galili, U., S. B. Shohet, E. Kobrin, C. L. M. Stults, and B. A. Macher. 1988. Man, apes, and Old World monkeys differ from other mammals in the expression of α-calactosyl epitopes on nucleated cells. J. Biol. Chem. 263:17755.
14. Galili, U., M. R. Clark, S. B. Shohet, J. Buehler, and B. A. Macher. 1987. Evolutionary relationship between the natural anti-Gal antibody and the Galα1-3Gal epitope in primates. Proc. Natl. Acad. Sci. USA 84:1369.
15. Galili, U. 1993. Evolution and pathophysiology of the human natural anti-α-calactosyl IgG (anti-Gal) antibody. Springer Semin. Immunopathol. 15:155.
16. Galili, U., E. A. Rachmilewitz, A. Peleg, and I. Flechner. 1984. A unique natural human IgG antibody with anti-α-galactosyl specificity. J. Exp. Med. 160:1519.
17. Joziasse, D. H., J. H. Shaper, D. H. Van den Eijnden, A. J. Van Tunen, and N. L. Shaper. 1989. Bovine α1-3-galactosyltransferase: isolation and characterisation of a cDNA clone. J. Biol. Chem. 264:14290.
18. Vaughan, H. A., B. E. Loveland, and M. S. Sandrin. 1994. Galα(1, 3)gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. Transplantation 58:879.
19. Markowitz, D., S. Goff, and A. Bank. 1988. A safe packaging line for gene transfer: separating viral genes on two different plasmids. J. Virol. 62:1120.
20. Ausubel, F. M., R. Brent, R. E. Kingston, D. D. Moore, J. G. Seidman, J. A. Smith, and K. Struhl. 1991. Current Protocols in Molecular Biology, Vol. 1. John Wiley & Sons, New York.
21. Miller, A. D., and C. Buttimore. 1986. Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6: 2895.
22. Gazdar, A. F., D. N. Carney, P. Z. Bunn, E. K. Russell, E. S. Jaffe, G. P. Schechter, and J. G. Guccion. 1980. Mitogen requirements for the in vitro propagation of cutaneous T-cell lymphomas. Blood 55:409.
23. + cell line H9. AIDS Res. Hum. Retroviruses 5:253.
24. Kimpton, J., and M. Emerman. 1992. Detection of replication competent and pseudotyped HIV with a sensitive cell line based on activation of an integrated beta-galactosidase gene. J. Virol. 66:2232.
25. Gorelik, E., L. Duty, F. Anaraki, and U. Galili. 1995. Alterations of cell surface carbohydrates and inhibition of metastatic property of murine melanomas by α1,3 galactosyltransferase gene transfection. Cancer Res. 55:4168.
26. Smith, D. F., R. D. Larsen, S. Mattox, J. B. Lowe, and R. D. Cummings. 1990. Transfer and expression of a murine UDP-Gal:β-D-Gal-α1,3-galactosyltransferase gene in transfected Chinese hamster ovary cells. J. Biol. Chem. 265:6225.
27. Neethling, F. A., E. Koren, Y. Ye, S. V. Richards, M. Kujundzic, R. Oriol, and D. K. C. Cooper. 1994. Protection of pig kidney (PK15) cells from the cytotoxic effect of anti-pig antibodies by α-galactosyl oligosaccharides. Transplantation 57:959.
28. Geyer, H., C. Holschback, G. Hunsmann and J. Schneider. 1988. Carbohydrates of human immunodeficiency virus: structures of oligosaccharides linked to the envelope glycoprotein 120. J. Biol. Chem. 263:11760.
29. Marschang, P., J. Sodroski, R. Wurzner, and M. P. Dierich. 1995. Decay-accelerating factor (CD55) protects human immunodeficiency virus type 1 from inactivation by human complement. Eur. J. Immunol. 25:285.
30. Saifuddin, M., C. J. Parker, M. E. Peeples, M. K. Gorny, S. Zolla-Pazner, M. Ghassemi, I. A. Rooney, J. P. Atkinson, and G. T. Spear. 1995. Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J. Exp. Med. 182:501.
31. Spear, G. T., N. S. Lurain, C. J. Parker, M. Ghassemi, G. H. Payne, and M. Saifuddin. 1995. Host cell-derived complement control proteins CD55 and CD59 are incorporated into the virions of two unrelated enveloped viruses. J. Immunol. 155:4376.
32. Galili, U., and P. Andrews. 1995. Suppression of α-galactosyl epitopes synthesis and production of the natural anti-Gal antibody: a major evolutionary event in ancestral Old World primates. J. Hum. Evol. 29:433.
33. Galili, U., R. E. Mandrell, R. M. Hamadeh, S. B. Shohet, and J. M. Griffis. 1988. Interaction between human natural anti-agalactosyl immunoglobulin G and bacteria of the human flora. Infect. Immun. 56:1730.
34. Almeida, I. C., S. R. Milani, A. J. Gorin, and L. R. Travoassos. 1991. Complement mediated lysis of Trypanosoma cruzi tryptomastigotes by human anti α-galactosyl antibodies. J. Immunol. 146:2394.
35. Repik, P. M., J. M. Strizki, and U. Galili. 1994. Differential host-dependent expression of α-galactosyl epitopes on viral glycoproteins: a study of eastern equine encephalitis virus as a model. J. Gen. Virol. 75:1177.
36. Geyer, R., H. Geyer, S. Stirm, G. Hensmann, J. Schneider, U. Dabrowski, and J. Dabrowski. 1984. Major oligosaccharides in the glycoprotein of Friend murine leukemia virus: structure elucidation by one- and two-dimensional proton nuclear magnetic resonance and methylation analysis. Biochemistry 23:5628.
37. Rother, R. P., and S. P. Squinto. 1996. The α-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Cell 86:185.
38. Cornetta, K., R. C. Moen, K. Culver, R. A. Morgan, J. R. McLachlin, S. Sturm, J. Selegue, W. London, R. M. Blaese, and W. F. Anderson. 1990. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum. Gene Ther. 1:15.
39. Cornetta, K., R. A. Morgan, A. Gillio, S. Sturm, L. Baltrucki, R. O'Reilly, and W. F. Anderson. 1991. No retroviremia or pathology in long-term follow-up of monkeys exposed to a murine amphotropic retrovirus. Hum. Gene Ther. 2:215.
40. Feng, Y., C. C. Broder, P. E. Kennedy, and E. A. Berger. 1996. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272:872.
41. Galili, U., P. M. Repik, F. Anaraki, K. Mozdzanowska, G. Washko, and W. Gerhard. 1996. Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody. Vaccine 14:321.